Management of Severe Rhabdomyolysis with Thrombotic Microangiopathy
Proceed immediately to kidney biopsy to establish the diagnosis, while simultaneously testing for ADAMTS13 activity and anti-PF4 antibodies, and discontinue all heparin products if the patient has received any anticoagulation.
Immediate Diagnostic Priorities
This 70-year-old woman presents with a constellation of findings suggesting thrombotic microangiopathy (TMA) superimposed on rhabdomyolysis-induced acute kidney injury. The combination of thrombocytopenia, anemia, heavy proteinuria (>5 grams), hematuria, and refractory acute kidney injury despite dialysis demands urgent TMA evaluation.
Critical Laboratory Tests to Order Now
- ADAMTS13 activity level and inhibitor titer must be sent urgently to differentiate thrombotic thrombocytopenic purpura (TTP) from other TMAs, as severely deficient activity (<10%) indicates TTP requiring immediate plasma exchange 1, 2, 3
- Peripheral blood smear for schistocytes is essential, though their absence does not exclude TMA due to low test sensitivity 1
- Complement testing including C3, C4, and CH50 to evaluate for complement-mediated atypical hemolytic uremic syndrome (aHUS), particularly given the negative ANCA and SPEP 1, 3
- Anti-PF4 antibodies to exclude heparin-induced thrombocytopenia (HIT), especially if the patient received any heparin during hospitalization or dialysis 4
- Hemolysis markers including LDH, haptoglobin, indirect bilirubin, and reticulocyte count to confirm microangiopathic hemolytic anemia 1, 2
- Direct antiglobulin test (Coombs) to exclude immune-mediated hemolysis 2
Kidney Biopsy is Essential
Proceed with kidney biopsy without delay to distinguish between:
- Acute tubular necrosis from rhabdomyolysis alone
- Acute tubulointerstitial nephritis (ATIN)
- Thrombotic microangiopathy affecting the glomeruli
- Glomerulonephritis (despite negative ANCA, other forms exist)
The biopsy will determine whether the heavy proteinuria and hematuria represent TMA-related glomerular injury versus another concurrent process 4. Early biopsy consideration is recommended as it may negate the need for empiric steroids and clarify the underlying pathology 4.
Empiric Treatment While Awaiting Results
If TTP is Suspected (Based on Clinical Presentation)
Do not wait for ADAMTS13 results if clinical suspicion is high. The decision to initiate plasma exchange should not be delayed, as mortality increases with treatment delay 1, 2, 3.
- Initiate therapeutic plasma exchange (TPE) immediately at 1-1.5 times plasma volume daily using fresh frozen plasma 2, 3
- Administer methylprednisolone 1g IV daily for 3 days, starting immediately after the first plasma exchange 1, 2, 3
- Continue TPE daily until platelet count >150,000/mm³ and LDH normalizes, then taper slowly 2
- Avoid platelet transfusions unless life-threatening bleeding occurs, as they may worsen thrombosis 2, 3
If Atypical HUS is More Likely
Given the severe renal involvement with heavy proteinuria and the negative ANCA/SPEP, complement-mediated aHUS is a strong consideration, particularly if ADAMTS13 returns >10% 1, 3.
- Begin eculizumab therapy urgently with dosing: 900 mg IV weekly for 4 doses, then 1,200 mg at week 5, followed by 1,200 mg every 2 weeks 1, 3, 5
- Administer meningococcal vaccination and initiate long-term penicillin prophylaxis immediately 1, 3
- In severe renal impairment (creatinine clearance <30 mL/min), eculizumab is the preferred complement inhibitor 5
If HIT is Possible
If the patient received any heparin products (including heparin flushes for dialysis catheters), calculate the 4T score 4:
- If 4T score ≥6 (high probability): Stop all heparin immediately and switch to argatroban without waiting for anti-PF4 antibody results 4
- In severe renal impairment (creatinine clearance <30 mL/min), only argatroban can be used among non-heparin anticoagulants 4
- Initial argatroban dose: 1 mcg/kg/min, reduced to 0.5 mcg/kg/min in critically ill patients 4
- Danaparoid is contraindicated as first-line treatment in severe renal failure 4
Supportive Care Measures
- Continue hemodialysis as needed for volume management and uremia 2
- Transfuse RBCs conservatively, targeting hemoglobin 7-8 g/dL in this stable, non-cardiac patient 1, 2, 3
- Provide folic acid 1 mg daily supplementation 2
- Monitor daily: CBC with differential, platelet count, LDH, haptoglobin, and creatinine 1
Critical Pitfalls to Avoid
- Do not dismiss TMA based on "few" schistocytes alone, as low schistocyte counts can occur in early or evolving TMA 1
- Do not delay plasma exchange while awaiting ADAMTS13 results if TTP is clinically suspected 1, 2, 3
- Do not transfuse platelets in suspected TTP/TMA unless life-threatening bleeding is present 2, 3
- Do not continue heparin if HIT is in the differential diagnosis with intermediate or high 4T score 4
- Do not assume rhabdomyolysis alone explains all findings—the combination of thrombocytopenia, anemia, and heavy proteinuria demands TMA investigation 1, 6, 7
Algorithm Summary
- Send ADAMTS13, complement levels, anti-PF4 antibodies, hemolysis markers, and peripheral smear immediately
- Arrange urgent kidney biopsy (within 24-48 hours if possible)
- If ADAMTS13 <10%: Start TPE + methylprednisolone
- If ADAMTS13 >10% with complement abnormalities: Start eculizumab + vaccination
- If heparin exposure + high 4T score: Stop heparin, start argatroban
- Continue dialysis and conservative RBC transfusion support
- Adjust therapy based on biopsy results and final laboratory confirmation
The persistently elevated CPK despite dialysis is concerning but secondary to the more immediately life-threatening TMA, which requires urgent diagnosis and treatment to prevent irreversible organ damage 1, 6, 7, 8.